Mr David Schnell, MD
Managing Director of Prospect Venture Partners. Prior to co-founding Prospect Venture Partners and establishing Prospect Venture Partners II, David was a Partner at Kleiner Perkins Caufield & Byers (KPCB) where he played a key role in the firm's investmen
Serves or has served on the Board of Directors of Healtheon, Metreo, Microcide, Neurocrine Biosciences, Rinat Neuroscience, Senomyx, Trine and several other privately-held companies.
MD from Harvard Medical School. MA in Health Services Research from Stanford University School of Medicine, and a BS in Biological Sciences from Stanford University.
Venture capital firm
PSEPS ID: 22292